Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis (ReCARE)

NCT02263066 COMPLETED

To assess and describe real-life treatment choices for rFⅧ contained regular prophylaxis/bleeding prevention treatment in pediatric hemophilia patients in China (2007-2013)

Details

Lead sponsor	Bayer
Status	COMPLETED
Enrolment	181
Start date	2014-10
Completion	2015-07

Conditions

• Hemophilia A

Interventions

• BAY14-2222_Kogenate-FS FVIII

Primary outcomes

• Duration of regular prophylaxis — Up to 1.5 years
• Prophylaxis infusion dose — Up to 1.5 years
• Percentage of rFVIII usage in prophylaxis — Up to 1.5 years

Countries

China